Elder Pharma 
Welcome,         Profile    Billing    Logout  
 5 Products   1 Disease  5 Products   6 Trials   161 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chymoral forte (trypsin/chymotrypsin) / Elder Pharma
NCT06562816: Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain

Recruiting
4
100
RoW
Trypsin-Chymotrypsin, Chymoral Forte, Naproxen Sodium 550mg, Synflex 550mg
Dow University of Health Sciences
Effect of Drug
11/24
01/25
Zalain (sertaconazole) / Elder Pharma
NCT06869681: Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis

Not yet recruiting
4
100
NA
Topical Sertaconazole 2%, Clotrimazole 1%
Jinnah Postgraduate Medical Centre
Tinea Pedis
05/25
06/25
Hibor (bemiparin) / ROVI Pharmaceuticals Laboratories, Elder Pharma
BRIF, NCT02607319: Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure

Completed
4
165
RoW
Bemiparin sodium, Hibor
American University of Beirut Medical Center
Sterility
07/22
07/22
2004-004826-28: Multicenter double-blind placebo controlled aleatorized study to evaluate the efficacy and safety of bemiparin (3500 IU/day) in thromboprophylaxis in cancer paients with central vein catheter

Ongoing
3
402
Europe
Hibor 3500 antiXA IU/day, Hibor 3500 antiXA IU/day
Instituto Científico y Tecnológico de Navarra
Deep Vein Thrombosis related central vein catheter (DVT-CVC)
 
 
2020-005884-29: ROLE OF HEPARIN IN THE PREVENTION OF THROMBOEMBOLISM IN PATIENTS WITH COVID-19 AND RESPIRATORY FAILURE RUOLO DELL'EPARINA NELLA PREVENZIONE DEL TROMBOEMBOLISMO IN PAZIENTI CON COVID-19 E INSUFFICIENZA RESPIRATORIA

Not yet recruiting
3
652
Europe
Parnaparina, Dalteparina, Nadroparina, Bemiparina, Reviparina, Enoxaparina, [Antitrombotici - derivati dell’eparina], Solution for injection
UNIVERSITà DEGLI STUDI DI PERUGIA
Patients with confirmed SARS-CoV-2 infection and respiratory failure will be randomized to receive two different doses of low molecular weight heparin (LMWH). Pazienti con infezione confermata da SARS-CoV-2 e insufficienza respiratoria saranno randomizzati a ricevere due diversi tipi di dosaggi di eparina a basso peso molecolare (EBPM)., Patients with confirmed SARS-CoV-2 infection and respiratory failure. Pazienti con infezione confermata da SARS-CoV-2 e insufficienza respiratoria., Diseases [C] - Virus Diseases [C02]
 
 
BEMICOP, NCT04604327: Comparison of Two Different Doses of Bemiparin in COVID-19

Recruiting
3
164
Europe
Bemiparin sodium, Hibor
Clinica Universidad de Navarra, Universidad de Navarra
COVID-19
05/21
07/21
MAFIC, NCT04508855: Management of Atrial Fibrillation in Patients With Cancer ( Study)

Withdrawn
N/A
240
Europe
Low molecular weight heparin
AHEPA University Hospital, Theagenio Cancer Hospital
Cancer, Atrial Fibrillation
08/23
12/23
NCT05569681: Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

Recruiting
N/A
2400
RoW
Bemiparin 3500, Hibor 3500 IU, Bemiparin 5000 IU, Hibor 5000 IU
Hawler Medical University
Morbid Obesity
02/26
04/26
Venex (diosmin) / Elder Pharma
2020-005461-14: Study of Acute myelogenic Leukemia (AML) treatment for patients who can not recieve intensiv chemotherapy combining standard treatment (Azacitidin ) with study medicine(low dose Venetoclax) for better responce and we will look at effect of medicines on leukemic cells and possible resistence developement to help find new ways for treatment Studie om behandling av Akutt Myelogen Leukemi(AML) med kombinasjon av Standard behandling (Azacytidine) med studiemedisin(Lavdose Venetoclax )hos pasienter som ikke kan få kraftig cellgiftbehandling

Ongoing
2
117
Europe
VENETOCLAX, Tablet, Venclyxto
Righospitalet, Rigshospitalet, Rigshospitalet, , NA
Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will use study medicine (low dose Venetoclax)in combination with standard treatment (Azacitidine) for better responce and survival and examine mechanism for drug sensitivity and resistence Akutt Myelogen Leukemi (AML) er agressiv type leukemia og behandlingen er ufordrende hos pasienter som ikke kan få intensiv cellgift behandling eller fått tilbakefall etter intensiv cellgift kurenI denne studien vil vi kombinere studiemedisin (lav dose Venetoclax )med Standard behandling(Azacitidin)for bedre responce og overlevelseVi vil også undersøkre mekanismer for medikament responce og resistence utvikling, AML is agressiv type blood cancer which is common in elderly and is challenging to treat specialy i patient who can not recieve intensiv chemotherapy or get relapsed disease after such therapy , AML er aggressiv type blodkreft vanligvis rammer eldre det er utfordrende å behandle spesielt hos pasienter som ikke kan få intensiv cellegift behandling eller fått tilbakefall etter slik behandling, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Megashelcal (omega 3 fatty acids) / Elder Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chymoral forte (trypsin/chymotrypsin) / Elder Pharma
NCT06562816: Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain

Recruiting
4
100
RoW
Trypsin-Chymotrypsin, Chymoral Forte, Naproxen Sodium 550mg, Synflex 550mg
Dow University of Health Sciences
Effect of Drug
11/24
01/25
Zalain (sertaconazole) / Elder Pharma
NCT06869681: Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis

Not yet recruiting
4
100
NA
Topical Sertaconazole 2%, Clotrimazole 1%
Jinnah Postgraduate Medical Centre
Tinea Pedis
05/25
06/25
Hibor (bemiparin) / ROVI Pharmaceuticals Laboratories, Elder Pharma
BRIF, NCT02607319: Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure

Completed
4
165
RoW
Bemiparin sodium, Hibor
American University of Beirut Medical Center
Sterility
07/22
07/22
2004-004826-28: Multicenter double-blind placebo controlled aleatorized study to evaluate the efficacy and safety of bemiparin (3500 IU/day) in thromboprophylaxis in cancer paients with central vein catheter

Ongoing
3
402
Europe
Hibor 3500 antiXA IU/day, Hibor 3500 antiXA IU/day
Instituto Científico y Tecnológico de Navarra
Deep Vein Thrombosis related central vein catheter (DVT-CVC)
 
 
2020-005884-29: ROLE OF HEPARIN IN THE PREVENTION OF THROMBOEMBOLISM IN PATIENTS WITH COVID-19 AND RESPIRATORY FAILURE RUOLO DELL'EPARINA NELLA PREVENZIONE DEL TROMBOEMBOLISMO IN PAZIENTI CON COVID-19 E INSUFFICIENZA RESPIRATORIA

Not yet recruiting
3
652
Europe
Parnaparina, Dalteparina, Nadroparina, Bemiparina, Reviparina, Enoxaparina, [Antitrombotici - derivati dell’eparina], Solution for injection
UNIVERSITà DEGLI STUDI DI PERUGIA
Patients with confirmed SARS-CoV-2 infection and respiratory failure will be randomized to receive two different doses of low molecular weight heparin (LMWH). Pazienti con infezione confermata da SARS-CoV-2 e insufficienza respiratoria saranno randomizzati a ricevere due diversi tipi di dosaggi di eparina a basso peso molecolare (EBPM)., Patients with confirmed SARS-CoV-2 infection and respiratory failure. Pazienti con infezione confermata da SARS-CoV-2 e insufficienza respiratoria., Diseases [C] - Virus Diseases [C02]
 
 
BEMICOP, NCT04604327: Comparison of Two Different Doses of Bemiparin in COVID-19

Recruiting
3
164
Europe
Bemiparin sodium, Hibor
Clinica Universidad de Navarra, Universidad de Navarra
COVID-19
05/21
07/21
MAFIC, NCT04508855: Management of Atrial Fibrillation in Patients With Cancer ( Study)

Withdrawn
N/A
240
Europe
Low molecular weight heparin
AHEPA University Hospital, Theagenio Cancer Hospital
Cancer, Atrial Fibrillation
08/23
12/23
NCT05569681: Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

Recruiting
N/A
2400
RoW
Bemiparin 3500, Hibor 3500 IU, Bemiparin 5000 IU, Hibor 5000 IU
Hawler Medical University
Morbid Obesity
02/26
04/26
Venex (diosmin) / Elder Pharma
2020-005461-14: Study of Acute myelogenic Leukemia (AML) treatment for patients who can not recieve intensiv chemotherapy combining standard treatment (Azacitidin ) with study medicine(low dose Venetoclax) for better responce and we will look at effect of medicines on leukemic cells and possible resistence developement to help find new ways for treatment Studie om behandling av Akutt Myelogen Leukemi(AML) med kombinasjon av Standard behandling (Azacytidine) med studiemedisin(Lavdose Venetoclax )hos pasienter som ikke kan få kraftig cellgiftbehandling

Ongoing
2
117
Europe
VENETOCLAX, Tablet, Venclyxto
Righospitalet, Rigshospitalet, Rigshospitalet, , NA
Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will use study medicine (low dose Venetoclax)in combination with standard treatment (Azacitidine) for better responce and survival and examine mechanism for drug sensitivity and resistence Akutt Myelogen Leukemi (AML) er agressiv type leukemia og behandlingen er ufordrende hos pasienter som ikke kan få intensiv cellgift behandling eller fått tilbakefall etter intensiv cellgift kurenI denne studien vil vi kombinere studiemedisin (lav dose Venetoclax )med Standard behandling(Azacitidin)for bedre responce og overlevelseVi vil også undersøkre mekanismer for medikament responce og resistence utvikling, AML is agressiv type blood cancer which is common in elderly and is challenging to treat specialy i patient who can not recieve intensiv chemotherapy or get relapsed disease after such therapy , AML er aggressiv type blodkreft vanligvis rammer eldre det er utfordrende å behandle spesielt hos pasienter som ikke kan få intensiv cellegift behandling eller fått tilbakefall etter slik behandling, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Megashelcal (omega 3 fatty acids) / Elder Pharma
No trials found

Download Options